Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YY003 for Moderate to Severe Glabellar Lines
NCT06481475Phase 2Completed
- Sponsor
- Claruvis Pharmaceutical
- Start
- Jan 2025
- Primary completion
- Oct 2025
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of yy003 in glabellar lines (3 arms), sponsored by Claruvis Pharmaceutical. Primary endpoints: Incidence of treatment-emergent adverse events at 4 weeks and Proportion of participants achieving a score of 0 or 1 and at least a two-grade improvement from baseline at 4 weeks. Started Jan 2025; status: completed.
02
Drugs
yy003
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT06481475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06481475.